Caxton Associates LP Sells 16,211 Shares of Pfizer Inc. (NYSE:PFE)

Caxton Associates LP cut its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 21.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 60,414 shares of the biopharmaceutical company's stock after selling 16,211 shares during the quarter. Caxton Associates LP's holdings in Pfizer were worth $1,603,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the fourth quarter worth about $26,000. Rialto Wealth Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth $26,000. Kohmann Bosshard Financial Services LLC acquired a new stake in shares of Pfizer in the fourth quarter valued at about $28,000. Noble Wealth Management PBC bought a new position in Pfizer during the fourth quarter worth $31,000. Finally, Curio Wealth LLC bought a new stake in shares of Pfizer in the 4th quarter valued at $32,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 0.5 %

PFE traded down $0.10 during midday trading on Wednesday, reaching $22.78. 48,160,808 shares of the company's stock traded hands, compared to its average volume of 40,426,421. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a fifty day moving average of $24.15 and a two-hundred day moving average of $25.65. The stock has a market capitalization of $129.18 billion, a price-to-earnings ratio of 16.15, a P/E/G ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. The business had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company's quarterly revenue was down 7.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.82 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Investors of record on Friday, May 9th will be issued a $0.43 dividend. The ex-dividend date is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.55%. Pfizer's payout ratio is currently 124.64%.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Citigroup reissued a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. UBS Group raised their price target on shares of Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Cantor Fitzgerald started coverage on Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target on the stock. Finally, The Goldman Sachs Group reissued a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have given a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Pfizer presently has a consensus rating of "Moderate Buy" and a consensus price target of $29.17.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm's stock in a transaction dated Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now directly owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.06% of the stock is currently owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.